Funding Opportunities

Intramural Funding Opportunities

  • Deadline: Mar 1, 2021
    UC Pancreatic Cancer Consortium (UCPCC) Collaborative Pilot Project Award

    The UCPCCC will fund a one-year pilot to encourage collaboration between UC campuses, with the expectation that it will lead to submission of a major collaborative grant such as an NIH P01, multi-PI R01, or similar. The goal of this solicitation is to promote the highest quality clinical, basic, or population science with translational potential. Projects must be devoted to the prevention, diagnosis and/or treatment of pancreatic neoplasia. Priority will be given to proposals that provide new approaches to important clinical or population/community challenges, or offer a clear route to a clinical trial.
  • Deadline: Mar 1, 2021
    UCSF Resource Allocation Program (RAP) Spring 2021 Cycle

    RAP offers a single online application process for a variety of intramural grants. Grants of interest include:
    • Cancer and Environmental Health Research Pilot Award ($50,000)
    • Pilot Award for Pancreas Cancer ($50,000)
    • Global Cancer Pilot Award ($40,000)
    • Pilot Award in Precision Imaging of Cancer and Therapy ($50,000)
    • Informing Tobacco Product Regulation ($50,000)
    • Independence Support Award ($50,000)
    • Pilots for Junior Investigators and Established Investigators in Basic and Clinical Sciences ($40,000 - 50,000)
  • Deadline: Mar 26, 2021
    Benioff Initiative for Prostate Cancer Research Award in Basic Science 

    Through a generous philanthropic gift, we are soliciting applications for funding research to understand the basic biological drivers of aggressive prostate cancer.
  • Deadline Mar 26, 2021
    Prostate Cancer Program Pilot Research Program

    The UCSF Prostate Cancer Program seeks to fund pilot projects in prostate cancer research. All areas of prostate cancer research at UCSF, including computational, laboratory, translational, clinical, and population science, are eligible. Proposals focusing on vulnerable populations are particularly encouraged.

Foundations/Other Sources

  • Deadline: March 24, 2021
    California Breast Cancer Research Program (CBCRP): A Community-Partnered Approach to Understanding the Social and Systemic Factors Influencing Breast Cancer Risk in Immigrants

    Why does immigrating from a country of low breast cancer incidence to the United States (and California) increase a women’s risk of breast cancer as well as the risk for her children and future generations? This initiative aims to answer this question through a community-partnered interdisciplinary approach focused on the systemic, social, and other interrelated factors influencing breast cancer risk for immigrants in California. 
  • Deadline: April 19, 2021
    NCCN Request for Proposals (RFP): Phase I/II Clinical and/or Correlative Studies of the panHER Inhibitor Neratinib in the Treatment of Breast, Gastrointestinal, Lung, and Neurological Cancers

    This research grant will support the conduct of clinical and correlative studies to evaluate the effectiveness of neratinib in the treatment of breast, gastrointestinal (GI), lung and certain neurological cancers. It is anticipated that proposals submitted in response to this RFP will be useful in guiding further clinical development of neratinib. Clinical studies with correlative endpoints are encouraged.
  • Deadline: April 22, 2021
    NCI/CRUK Cancer Grand Challenges

    The National Cancer Institute (NCI) and Cancer Research UK (CRUK), the world’s leading funders of cancer research, are partnering to fund the Cancer Grand Challenges (CGC) program. Cancer Grand Challenges will fund novel ideas by multidisciplinary research teams from around the world that offer the potential to advance bold cancer research and improve outcomes for people affected by cancer.
  • Deadline: rolling basis through Jan 31, 2022
    Partnership for Accelerating Cancer Therapies (PACT) Clinical Trials RFA 

    The Foundation for the NIH has issued an RFA for novel biomarkers to support the Partnership for Accelerating Cancer Therapies (PACT). The overall goal for this RFA is to solicit clinical trials to partner with the PACT initiative to provide biospecimens for exploratory deep immunoprofiling analysis, employing this standardized set of biomarker assays. The data from this immunoprofiling, along with the necessary de-identified clinical data from the trials, will be placed into the CIDC to continue to build a large body of standardized immunoprofiling data that can be used to validate existing biomarkers for clinical trial and regulatory use, and importantly, to develop new validated biomarkers for these purposes. Development and validation of these biomarkers will allow the immuno-oncology field to more accurately pair patients with novel immunotherapies being developed.